TNFα
41 programs · 40 companies
Programs
41
Companies
40
Active Trials
20
Targeting TNFα
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| ABB-3951 | AbbVie | Phase 2/3 | CTCLHNSCC | |
| GIL-6239 | Gilead Sciences | Phase 2 | GIST | |
| MRN-8225 | Moderna | Preclinical | CSUMS | |
| Sovanaritide | Argenx | Phase 3 | TTR AmyloidosisMG | |
| 369-4107 | Hansoh Pharma | Phase 2 | DravetIPF | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | Epilepsy | |
| APG-2066 | Apogee Ther | Phase 2 | GBMCTCL | |
| 452-308 | Eisai | NDA/BLA | AMLAtopic Derm | |
| 452-5750 | Ono Pharma | NDA/BLA | CSU | |
| Zanunaritide | Luye Pharma | Phase 1/2 | FSGS | |
| MAY-IIT-189 | Mayo Clinic | Approved | Thymoma | |
| ECO-IIT-552 | ECOG-ACRIN | Phase 2/3 | PsA | |
| EOR-IIT-912 | EORTC | Phase 1 | Hemophilia A | |
| STA-IIT-458 | Stanford Medicine | Phase 3 | HS | |
| INS-8557 | Insilico Medicine | Phase 2/3 | NarcolepsyGastric Ca | |
| ACI-1988 | AC Immune | Phase 1 | PsA | |
| Olpatinib | Emergent Bio | NDA/BLA | Crohn'sDravet | |
| GOS-5370 | Gossamer Bio | Phase 2/3 | Parkinson'sPV | |
| Gelirasimod | NexImmune | Phase 3 | WilmsSchizophrenia | |
| Tiralucimab | Kinnate Bio | Phase 2 | MesoNarcolepsy | |
| Zenotuximab | Galena Biopharma | Phase 1/2 | RCC | |
| Lisolemzoparlimab | BioNova Pharma | Phase 1 | MM | |
| Zenoosocimab | BioNova | Phase 1 | RABreast Ca | |
| Elrarasimod | Vesalius | NDA/BLA | Asthma | |
| Lisofotisoran | Natera | Approved | RAACC | |
| PMV-3715 | PMV Pharma | Phase 2/3 | SLEMelanoma | |
| LPC-975 | Lupin | Phase 2/3 | HNSCCAsthma | |
| Polazasiran | Gland Pharma | Preclinical | Prostate Ca | |
| PAR-6401 | Paradigm Bio | Phase 1 | PsA | |
| Daracilimab | TherapeuticsMD | Preclinical | AngelmanPAH | |
| MOR-6182 | Morphosys (Novartis) | Phase 1/2 | HSThymoma | |
| Lisoderotide | Reaction Biology | Phase 3 | FTDUrothelial Ca | |
| IRC-IIT-452 | IRCCS San Raffaele | Phase 1 | Gastric Ca | |
| NAT-IIT-525 | Natl Cancer Ctr Singapore | Phase 1/2 | DLBCL | |
| SEV-IIT-593 | Severance Hospital | Phase 1 | Ovarian Ca | |
| NAT-IIT-995 | National Univ Hospital | Approved | MCC | |
| NAT-IIT-319 | National Univ Hospital | Phase 1 | MG | |
| KIN-IIT-791 | King Faisal Spec Hosp | Approved | Breast Ca | |
| Elrasacituzumab | InnoCare | NDA/BLA | HSNSCLC | |
| WST-3921 | West Pharma | Phase 2/3 | SLEAtopic Derm | |
| Polafotisoran | SK Biopharm | NDA/BLA | HSThymoma |